Valuation: MYOS Corp

Market Cap 7.25M 6.44M 5.97M 5.43M 10.25M 688M 10.41M 71.76M 28.14M 359M 27.2M 26.62M 1.14B P/E 2021
-1.04x
P/E 2022 -0.41x
Enterprise Value 2.88M 2.56M 2.37M 2.16M 4.07M 273M 4.14M 28.5M 11.17M 143M 10.8M 10.57M 454M EV / Sales 2021
1.74x
EV / Sales 2022 0.46x
Free-Float
-
Yield 2021 *
-
Yield 2022 -

Financials

2021 2022
Net sales 22.13M 19.67M 18.23M 16.59M 31.3M 2.1B 31.8M 219M 85.92M 1.1B 83.05M 81.28M 3.49B 43.11M 38.32M 35.52M 32.31M 60.98M 4.09B 61.96M 427M 167M 2.14B 162M 158M 6.81B
Net income -43.82M -38.95M -36.1M -32.84M -61.98M -4.16B -62.97M -434M -170M -2.17B -164M -161M -6.92B -47.62M -42.33M -39.23M -35.69M -67.35M -4.52B -68.43M -472M -185M -2.36B -179M -175M -7.52B
Net Debt -7.44M -6.62M -6.13M -5.58M -10.53M -706M -10.7M -73.7M -28.9M -369M -27.93M -27.34M -1.17B -4.37M -3.88M -3.6M -3.28M -6.18M -415M -6.28M -43.27M -16.96M -216M -16.4M -16.05M -690M
Logo MYOS Corp
MYOS RENS Technology Inc. is focused on the discovery, development and commercialization of nutritional ingredients, functional foods, and other technologies for maintaining or improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle-related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement that has been shown in clinical studies to temporarily decrease the levels of serum myostatin, MYO-T12, a formulation containing Fortetropin. Fortetropin is the Company's all-natural food ingredient clinically shown to enhance muscle size, lean body mass and strength as part of resistance training in humans. Fortetropin is made from fertilized chicken egg yolks using a process that retains the biological integrity and bioactivity of the product.
Employees
-
Sector
-